Ambrx Biopharma Inc.

NYSE: AMAM · Real-Time Price · USD
28.00
0.02 (0.07%)
At close: Mar 06, 2024, 10:00 PM

Ambrx Biopharma Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022
Period Ending Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Net Income
-67.06M -59.63M -70.65M -78M -67.06M -51.49M -22.65M
Depreciation & Amortization
1.49M 1.43M 1.61M 1.8M 1.43M 1.1M 558K
Stock-Based Compensation
10.83M 7.55M 6.54M 6.25M 5.07M 3.53M 1.65M
Other Working Capital
-6.1M -5.53M -4.57M -7.2M -5.66M -4.7M -7.22M
Other Non-Cash Items
2.43M 2.67M 9.61M 12.34M 11.66M 10.73M 3.15M
Deferred Income Tax
278K -481K -453K -453K -233K n/a n/a
Change in Working Capital
-5.67M -6.14M -2.63M -10.62M -6.84M -4.07M -8.37M
Operating Cash Flow
-57.7M -54.6M -55.98M -68.67M -55.97M -40.2M -25.66M
Capital Expenditures
-1.13M -934K -280K -1.05M -1.01M -903K -774K
Cash Acquisitions
-8.82M -20.8M -20.8M -20.8M -11.98M n/a n/a
Purchase of Investments
-50.07M -62.2M -125.5M -84.85M -75.43M -63.3M n/a
Sales Maturities Of Investments
113.83M 119.35M 109.39M 39.19M 11.98M n/a n/a
Other Investing Acitivies
8.82M 20.8M 20.8M 20.8M 11.98M n/a n/a
Investing Cash Flow
62.64M 56.22M -16.39M -46.72M -64.46M -64.2M -774K
Debt Repayment
n/a n/a n/a n/a n/a n/a n/a
Common Stock Repurchased
n/a n/a n/a n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a n/a n/a n/a
Other Financial Acitivies
170.06M 160.83M 78.16M 928K 447K -34K -6K
Financial Cash Flow
170.06M 160.83M 78.16M 928K 447K -34K -6K
Net Cash Flow
174.01M 162.46M 5.79M -114.47M -118.99M -104.43M -26.44M
Free Cash Flow
-58.83M -55.53M -56.26M -69.73M -56.98M -41.1M -26.44M